Abstract：Objective To investigate the efficacy of trastuzumab combined with Sox chemotherapy in the treatment of advanced gastric cancer with positive human epidermal growth factor receptor-2（HER-2）and its effect on progression free survival（PFS）. Methods 116 patients with HER-2 positive advanced gastric cancer were randomly divided into two groups,58 cases in each group.The control group was given Sox chemotherapy,and the observation group was given trastuzumab combined with Sox chemotherapy.The clinical efficacy,adverse reactions（leucopenia,neutropenia,thrombocytopenia,anemia,nausea,vomiting,mucositis）and PFS were compared between the two groups. Results After treatment,the Objective remission rate（RR）and disease control rate（DCR）of the observation group were 67.24% and 89.66%,respectively,which were higher than 48.28% and 72.41% of the control group,the difference was statistically significant（P<0.05）;during the treatment,there was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）;the PFS time in the observation group was longer than that in the control group,the difference was statistically significant（P<0.05）. Conclusion Trastuzumab combined with Sox chemotherapy regimen can effectively improve the clinical efficacy of the treatment of HER-2 positive advanced gastric cancer,prolong the PFS time of patients,and do not significantly increase the toxicity and side effects,which is worthy of clinical promotion.
2021, Vol. 41 
